Fortress Biotech Inc (FBIO)

$2.52 -0.05 (-1.95%)
Market Cap 84.05M
Revenue (ttm) 63.26M
Net Income (ttm) 6.82M
EPS (ttm) N/A
PE Ratio 0.97
Forward PE N/A
Profit Margin 10.78%
Debt to Equity Ratio 0.17
Volume 209,700
Avg Vol 582,454
Day's Range N/A - N/A
Shares Out 33.35M
Stochastic %K 0%
Beta 1.19
Analysts Strong Sell
Price Target $11.00

Company Profile

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular m...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
et1000
et1000 Sep. 11 at 11:15 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $ABCL $FBIO $SNDX $TGTX :A
0 · Reply
braves1983
braves1983 Sep. 11 at 11:05 PM
$FBIO Still a pile of shit here. 20k shares for nothing.
0 · Reply
FinSUN
FinSUN Sep. 11 at 5:02 PM
$FBIO
0 · Reply
Waters59
Waters59 Sep. 11 at 2:18 PM
$FBIO Now can you bounce with me, bounce with me, Can you bounce with me, bounce with me, ge-gi-gi-gi-gi-gi, Can you bounce with me, bounce with me Let's Go! 📈
0 · Reply
braves1983
braves1983 Sep. 11 at 12:36 AM
$FBIO 2.50s now. No where near $3 or that bullshit price target
0 · Reply
FinSUN
FinSUN Sep. 10 at 6:33 PM
$FBIO
1 · Reply
braves1983
braves1983 Sep. 10 at 5:54 PM
$FBIO fuck yea. Keep going down.
0 · Reply
braves1983
braves1983 Sep. 10 at 4:59 PM
$FBIO holy fuck already. Like what the fuck is up here. Like everyday it’s fucking down
0 · Reply
braves1983
braves1983 Sep. 10 at 2:51 PM
$FBIO has to be the 176th red day in a row here. Fuck
0 · Reply
Pharm_Hand
Pharm_Hand Sep. 10 at 10:18 AM
$FBIO Another poop slushie kinda day in Fortressville
0 · Reply
Latest News on FBIO
Journey Medical Corporation to Participate in September 2026 Investor Conferences

Sep 8, 2026, 4:05 PM EDT - 5 days ago

Journey Medical Corporation to Participate in September 2026 Investor Conferences

DERM

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 8, 2026, 8:00 AM EDT - 5 days ago

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

FBIOP

Fortress Biotech Slides: Corporate presentation

Sep 8, 2026, 8:00 AM EDT - 5 days ago

Fortress Biotech Slides: Corporate presentation

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Aug 13, 2026, 4:05 PM EDT - 4 weeks ago

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

FBIOP

Fortress Biotech Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 4 weeks ago

Fortress Biotech Earnings Call Transcript: Q2 2026

Fortress Biotech Quarterly report: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 4 weeks ago

Fortress Biotech Quarterly report: Q2 2026

Fortress Biotech Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 4 weeks ago

Fortress Biotech Earnings release: Q2 2026

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Aug 12, 2026, 4:01 PM EDT - 4 weeks ago

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

DERM

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

Aug 5, 2026, 8:30 AM EDT - 5 weeks ago

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

DERM

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing

Jul 27, 2026, 8:00 AM EDT - 6 weeks ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing

Fortress Biotech Transcript: AGM 2026

Jun 17, 2026, 10:00 AM EDT - 2 months ago

Fortress Biotech Transcript: AGM 2026

Fortress Biotech Slides: Corporate presentation

Jun 8, 2026, 7:00 AM EDT - 3 months ago

Fortress Biotech Slides: Corporate presentation

Fortress Biotech Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 20, 2026, 12:20 PM EDT - 3 months ago

Fortress Biotech Transcript: A.G.P.'s Annual Virtual Healthcare Conference

Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

May 19, 2026, 4:45 PM EDT - 3 months ago

Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

DERM

Fortress Biotech price target raised to $5 from $4.50 at Alliance Global

2026-05-18T13:00:31.000Z - 3 months ago

Fortress Biotech price target raised to $5 from $4.50 at Alliance Global

DERM

Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

May 18, 2026, 8:30 AM EDT - 3 months ago

Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

FBIOP

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026, 4:10 PM EDT - 4 months ago

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

FBIOP

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 13, 2026, 4:01 PM EDT - 4 months ago

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

DERM

Fortress Biotech Earnings Call Transcript: Q1 2026

May 13, 2026, 4:00 PM EDT - 4 months ago

Fortress Biotech Earnings Call Transcript: Q1 2026

Fortress Biotech Quarterly report: Q1 2026

May 13, 2026, 4:00 PM EDT - 4 months ago

Fortress Biotech Quarterly report: Q1 2026

Fortress Biotech Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 4 months ago

Fortress Biotech Earnings release: Q1 2026

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

May 6, 2026, 4:01 PM EDT - 4 months ago

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

DERM

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

May 4, 2026, 8:30 AM EDT - 4 months ago

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

FBIOP

Fortress Biotech Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Fortress Biotech Proxy statement: Proxy filing

Fortress Biotech Proxy statement: Proxy filing

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Fortress Biotech Proxy statement: Proxy filing

Fortress Biotech Slides: Corporate presentation

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Fortress Biotech Slides: Corporate presentation

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Apr 21, 2026, 8:30 AM EDT - 4 months ago

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

DERM

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Mar 31, 2026, 4:05 PM EDT - 5 months ago

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

FBIOP

Fortress Biotech Earnings release: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 5 months ago

Fortress Biotech Earnings release: Q4 2025

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Mar 30, 2026, 4:05 PM EDT - 5 months ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Mar 25, 2026, 4:01 PM EDT - 5 months ago

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

DERM

Fortress Biotech Slides: Corporate presentation

Mar 19, 2026, 7:00 AM EDT - 5 months ago

Fortress Biotech Slides: Corporate presentation

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Mar 18, 2026, 8:30 AM EDT - 5 months ago

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

DERM

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Feb 23, 2026, 9:24 AM EST - 6 months ago

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

2026-02-23T13:53:18.000Z - 6 months ago

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Feb 23, 2026, 8:30 AM EST - 6 months ago

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

FBIOP

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Feb 23, 2026, 8:00 AM EST - 6 months ago

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Fortress Biotech, Cyprium announce FDA approval of ZYCUBO

2026-01-13T12:50:22.000Z - 8 months ago

Fortress Biotech, Cyprium announce FDA approval of ZYCUBO

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Jan 13, 2026, 7:45 AM EST - 8 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

FBIOP

Fortress Biotech Registration statement: Registration Filing

Dec 16, 2025, 7:00 AM EST - 9 months ago

Fortress Biotech Registration statement: Registration Filing

Fortress Biotech files to sell 600,000 shares of common stock for holders

2025-12-16T11:11:34.000Z - 9 months ago

Fortress Biotech files to sell 600,000 shares of common stock for holders

Fortress Biotech, Cyprium announce FDA acceptance of CUTX-101 NDA resubmission

2025-12-15T13:10:58.000Z - 9 months ago

Fortress Biotech, Cyprium announce FDA acceptance of CUTX-101 NDA resubmission

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Dec 15, 2025, 8:00 AM EST - 9 months ago

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Dec 10, 2025, 8:30 AM EST - 9 months ago

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

DERM

Fortress Biotech price target raised to $4.50 from $4 at Alliance Global

2025-11-19T12:15:57.000Z - 9 months ago

Fortress Biotech price target raised to $4.50 from $4 at Alliance Global

Fortress Biotech reports Q3 EPS 11c vs (76c) last year

2025-11-14T13:40:48.000Z - 10 months ago

Fortress Biotech reports Q3 EPS 11c vs (76c) last year

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 14, 2025, 8:30 AM EST - 10 months ago

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Fortress Biotech Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Fortress Biotech Earnings Call Transcript: Q3 2025

Fortress Biotech Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Fortress Biotech Quarterly report: Q3 2025

Fortress Biotech Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Fortress Biotech Earnings release: Q3 2025

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 12, 2025, 4:01 PM EST - 10 months ago

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Nov 6, 2025, 7:00 AM EST - 10 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

AXSM

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

DERM

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Oct 24, 2025, 8:30 AM EDT - 10 months ago

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

DERM

Fortress subsidiary announces Crystalys dosed patient in study of dotinurad

2025-10-21T12:35:27.000Z - 10 months ago

Fortress subsidiary announces Crystalys dosed patient in study of dotinurad

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

Oct 21, 2025, 8:30 AM EDT - 10 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout

FBIOP

Journey Medical Corporation to Participate in October 2025 Investor Conferences

Oct 8, 2025, 8:30 AM EDT - 11 months ago

Journey Medical Corporation to Participate in October 2025 Investor Conferences

DERM

Fortress Biotech Investigated by the Portnoy Law Firm

Oct 1, 2025, 3:45 PM EDT - 11 months ago

Fortress Biotech Investigated by the Portnoy Law Firm

Why Is Fortress Biotech Stock (FBIO) Down 30% Today?

2025-10-01T13:07:24.000Z - 11 months ago

Why Is Fortress Biotech Stock (FBIO) Down 30% Today?

Fortress Biotech, Urica announces Crystalys’ $205M Series A financing

2025-10-01T12:30:16.000Z - 11 months ago

Fortress Biotech, Urica announces Crystalys’ $205M Series A financing

Fortress Biotech, Cyprium receive CRL related to NDA for CUTX-101

2025-10-01T12:11:28.000Z - 11 months ago

Fortress Biotech, Cyprium receive CRL related to NDA for CUTX-101

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

Oct 1, 2025, 8:05 AM EDT - 11 months ago

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

FBIOP

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

Oct 1, 2025, 8:00 AM EDT - 11 months ago

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

FBIOP

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Sep 3, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Participate in September 2025 Investor Conferences

DERM

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 1 year ago

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FBIOP

Fortress Biotech price target lowered to $17 from $26 at H.C. Wainwright

2025-08-21T10:20:36.000Z - 1 year ago

Fortress Biotech price target lowered to $17 from $26 at H.C. Wainwright

Fortress Biotech price target lowered to $12 from $15 at Roth Capital

2025-08-19T12:15:37.000Z - 1 year ago

Fortress Biotech price target lowered to $12 from $15 at Roth Capital

Journey Medical Corporation to Present at the Emerging Growth Conference

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Present at the Emerging Growth Conference

DERM

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Fortress Biotech Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Quarterly report: Q2 2025

Fortress Biotech Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Earnings release: Q2 2025

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

DERM

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Aug 5, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

DERM

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Jul 14, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

DERM

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

DERM

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Jun 20, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

DERM

Fortress Biotech Transcript: AGM 2025

Jun 17, 2025, 10:00 AM EDT - 1 year ago

Fortress Biotech Transcript: AGM 2025

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

Jun 9, 2025, 8:30 AM EDT - 1 year ago

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

DERM

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

May 30, 2025, 10:47 AM EDT - 1 year ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIOP

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 15, 2025, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIOP

Fortress Biotech Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Quarterly report: Q1 2025

Fortress Biotech Earnings release: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Fortress Biotech Earnings release: Q1 2025

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 14, 2025, 4:01 PM EDT - 1 year ago

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

DERM

Fortress Biotech management to meet virtually with Roth MKM

2025-05-08T15:45:41.000Z - 1 year ago

Fortress Biotech management to meet virtually with Roth MKM

Fortress Biotech Slides: Corporate presentation

May 1, 2025, 9:00 AM EDT - 1 year ago

Fortress Biotech Slides: Corporate presentation

Fortress Biotech Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech Proxy statement: Proxy Filing

Fortress Biotech Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech Proxy statement: Proxy Filing

Fortress Biotech Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Fortress Biotech Proxy statement: Proxy Filing

Fortress Biotech Annual report: Q4 2024

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Fortress Biotech Annual report: Q4 2024

Fortress Biotech Earnings release: Q4 2024

Mar 26, 2025, 4:30 PM EDT - 1 year ago

Fortress Biotech Earnings release: Q4 2024

Fortress Biotech, Partex enter collaboration for asset identification

2025-03-17T13:07:15.000Z - 1 year ago

Fortress Biotech, Partex enter collaboration for asset identification

Fortress Biotech, Partex enter collaboration for asset identification, evaluatio

2025-03-17T13:00:50.000Z - 1 year ago

Fortress Biotech, Partex enter collaboration for asset identification, evaluatio

et1000
et1000 Sep. 11 at 11:15 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $ABCL $FBIO $SNDX $TGTX :A
0 · Reply
braves1983
braves1983 Sep. 11 at 11:05 PM
$FBIO Still a pile of shit here. 20k shares for nothing.
0 · Reply
FinSUN
FinSUN Sep. 11 at 5:02 PM
$FBIO
0 · Reply
Waters59
Waters59 Sep. 11 at 2:18 PM
$FBIO Now can you bounce with me, bounce with me, Can you bounce with me, bounce with me, ge-gi-gi-gi-gi-gi, Can you bounce with me, bounce with me Let's Go! 📈
0 · Reply
braves1983
braves1983 Sep. 11 at 12:36 AM
$FBIO 2.50s now. No where near $3 or that bullshit price target
0 · Reply
FinSUN
FinSUN Sep. 10 at 6:33 PM
$FBIO
1 · Reply
braves1983
braves1983 Sep. 10 at 5:54 PM
$FBIO fuck yea. Keep going down.
0 · Reply
braves1983
braves1983 Sep. 10 at 4:59 PM
$FBIO holy fuck already. Like what the fuck is up here. Like everyday it’s fucking down
0 · Reply
braves1983
braves1983 Sep. 10 at 2:51 PM
$FBIO has to be the 176th red day in a row here. Fuck
0 · Reply
Pharm_Hand
Pharm_Hand Sep. 10 at 10:18 AM
$FBIO Another poop slushie kinda day in Fortressville
0 · Reply
IBUYSELLHOLD
IBUYSELLHOLD Sep. 9 at 9:21 PM
$FBIO / daddy's waiting
1 · Reply
braves1983
braves1983 Sep. 9 at 1:50 PM
$FBIO we ever going to see $3 here? Like ever??
0 · Reply
StockBodega
StockBodega Sep. 9 at 10:28 AM
$DERM $FBIO $FBIOP https://finance.yahoo.com/healthcare/articles/journey-medical-corporation-participate-september-200500610.html
0 · Reply
Pharm_Hand
Pharm_Hand Sep. 8 at 11:07 AM
$FBIO A runny bowels snow cone
0 · Reply
Merlintrader
Merlintrader Sep. 7 at 6:15 AM
Fortress Biotech ($FBIO): Can Emrosi Growth Build Lasting Per-Share Value? Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/fortress-biotech-fbio-stock-hub/
0 · Reply
Pharm_Hand
Pharm_Hand Sep. 4 at 11:20 AM
$FBIO Poop on an all terrain tire.
0 · Reply
braves1983
braves1983 Sep. 3 at 4:23 PM
$FBIO keep going down. 2.60s next. Farther and farther from $3
0 · Reply
makrodimutross
makrodimutross Sep. 2 at 1:30 AM
$FBIO $FBIOP Millennium Management LLC reporting a (new?) 5% position in the company with 1,778,561 shares. Wow.
3 · Reply
CamelMoneyMaker
CamelMoneyMaker Sep. 2 at 1:24 AM
I rarely trade penny stocks but $FBIO $FMFC $RLYB these tickers passed the “Graham-NCAV test” Worth keeping them on your watchlist
0 · Reply
braves1983
braves1983 Sep. 1 at 2:08 PM
$FBIO nothing new here. Still red. Always red. This has to be like a fucking record of red days.
1 · Reply
FinSUN
FinSUN Sep. 1 at 1:39 PM
$FBIO buying back under $2
1 · Reply
braves1983
braves1983 Aug. 31 at 10:11 PM
$FBIO does anyone here me?? Does anyone work for this company??
1 · Reply